SCHEMBL5478682

SCHEMBL5478682

O=C1/C(=C/c2c[nH]c3ccccc23)c2ccccc2N1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 3/20 0.55
KDR P35968 2/20 0.55
RET P07949 2/20 0.55
DAPK3 O43293 1/20 0.55
PRKD3 O94806 1/20 0.55
MAP4K4 O95819 1/20 0.55
ABL1 P00519 1/20 0.55
LCK P06239 1/20 0.55
FYN P06241 1/20 0.55
CSF1R P07333 1/20 0.55
PDGFRB P09619 1/20 0.55
PDGFRA P16234 1/20 0.55
LTK P29376 1/20 0.55
GRK5 P34947 1/20 0.55
FLT3 P36888 1/20 0.55
MAPK8 P45983 1/20 0.55
CSNK1A1 P48729 1/20 0.55
CDK7 P50613 1/20 0.55
RPS6KA3 P51812 1/20 0.55
LIMK1 P53667 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14448859 1.00 NTRK1 (0.55) NTRK1KDRRETDAPK3PRKD3
SCHEMBL5478687 1.00 NTRK1 (0.55) NTRK1KDRRETDAPK3PRKD3
SCHEMBL7783118 0.84 NTRK1 (0.55) NTRK1KDRRETDAPK3PRKD3
SCHEMBL7694409 0.84 NTRK1 (0.52) NTRK1KDRRETDAPK3PRKD3
SCHEMBL27175573 0.82 ACHE (0.55) NTRK1KDRRETDAPK3PRKD3
SCHEMBL5468602 0.77 MAPT (0.47) NTRK1KDRRETDAPK3PRKD3
SCHEMBL14448846 0.77 MAPT (0.47) NTRK1KDRRETDAPK3PRKD3
SCHEMBL5468598 0.77 MAPT (0.47) NTRK1KDRRETDAPK3PRKD3
SCHEMBL5822217 0.76 NTRK1 (0.46) NTRK1KDRRETDAPK3PRKD3
SCHEMBL5822216 0.76 NTRK1 (0.46) NTRK1KDRRETDAPK3PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
WO-2006105795-A1 NOVEL INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2006-10-12 WO disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 NTRK1 175/4885KDR 4334/4885RET 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.